Alle verbonden artikelen

A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.

Auteurs : Martin M, Bonneterre J, Geyer CE, Ito Y, Ro J, Lang I, Kim SB, Germa C, Vermette J, Wang K, Awada A
Jaar : 2013
Journal : Eur. J. Cancer
Volume : 49(18)
Pagina's : 3763-72

Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting.

Auteurs : Peeters DJ, De Laere B, Van den Eynden GG, Van Laere SJ, Rothé F, Ignatiadis M, Sieuwerts AM, Lambrechts D, Rutten A, van Dam PA, Pauwels P, Peeters M, Vermeulen PB, Dirix LY
Jaar : 2013
Journal : Br J Cancer
Volume : 108(6)
Pagina's : 1358-67

Deep sequencing reveals abundant noncanonical retroviral microRNAs in B-cell leukemia/lymphoma.

Auteurs : Rosewick N, Momont M, Durkin K, Takeda H, Caiment F, Cleuter Y, Vernin C, Mortreux F, Wattel E, Burny A, Georges M, Van den Broeke A
Jaar : 2013
Journal : Proc. Natl. Acad. Sci. U.S.A.
Volume : 110(6)
Pagina's : 2306-11

The effect of communication skills training on residents' physiological arousal in a breaking bad news simulated task.

Auteurs : Meunier J, Merckaert I, Libert Y, Delvaux N, Etienne AM, Liénard A, Bragard I, Marchal S, Reynaert C, Slachmuylder JL, Razavi D
Jaar : 2013
Journal : Patient Educ Couns
Volume : 93(1)
Pagina's : 40-7

Association between SPARC mRNA Expression, Prognosis and Response to Neoadjuvant Chemotherapy in Early Breast Cancer: A Pooled in-silico Analysis.

Auteurs : Azim HA, Singhal S, Ignatiadis M, Desmedt C, Fumagalli D, Veys I, Larsimont D, Piccart-Gebhart M, Michiels S, Sotiriou C
Jaar : 2013
Journal : PLoS One
Volume : 8(4)
Pagina's : e62451

Emerging targeted agents in metastatic breast cancer.

Auteurs : Zardavas D, Baselga J, Piccart-Gebhart M
Jaar : 2013
Journal : Nat Rev Clin Oncol
Volume : 10(4)
Pagina's : 191-210

Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer.

Auteurs : Loi S, Michiels S, Lambrechts D, Fumagalli D, Claes B, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Piccart-Gebhart M, Joensuu H, Sotiriou C
Jaar : 2013
Journal : J. Natl. Cancer Inst.
Volume : 105(13)
Pagina's : 960-967

Pomalidomide plus low dose dexamethasone is active and well tolerated in bortezomib and lenalidomide refractory multiple myeloma: IFM 2009-02.

Auteurs : Leleu X, Attal M, Arnulf B, Moreau P, Traulle C, Marit G, Mathiot C, Petillon MO, Macro M, Roussel M, Pegourie B, Kolb B, Stoppa AM, Hennache B, Bréchignac S, Meuleman N, Thielemans B, Garderet L, Royer B, Hulin C, Benboubker L, Decaux O, Escoffre-Barbe M, Michallet M, Caillot D, Fermand JP, Avet-Loiseau H, Facon T
Jaar : 2013
Journal : Blood
Volume : 121(11)
Pagina's : 1968-75

Is it possible to improve the breaking bad news skills of residents when a relative is present? A randomised study.

Auteurs : Merckaert I, Liénard A, Libert Y, Bragard I, Delvaux N, Etienne AM, Marchal S, Meunier J, Reynaert C, Slachmuylder JL, Razavi D
Jaar : 2013
Journal : Br J Cancer
Volume : 109(10)
Pagina's : 2507-14

Change in the microenvironment of breast cancer studied by FTIR imaging.

Auteurs : Kumar S, Desmedt C, Larsimont D, Sotiriou C, Goormaghtigh E
Jaar : 2013
Journal : Analyst
Volume : 138(14)
Pagina's : 4058-65

Personalized therapy for breast cancer: a dream or a reality?

Auteurs : Zardavas D, Pugliano L, Piccart-Gebhart M
Jaar : 2013
Journal : Future Oncol
Volume : 9(8)
Pagina's : 1105-19

Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer.

Auteurs : Metzger-Filho O, Catteau A, Michiels S, Buyse M, Ignatiadis M, Saini KS, de Azambuja E, Fasolo V, Naji S, Canon JL, Delrée P, Coibion M, Cusumano P, Jossa V, Kains JP, Larsimont D, Richard V, Faverly D, Cornez N, Vuylsteke P, Vanderschueren B, Peyro-Saint-Paul H, Piccart-Gebhart M, Sotiriou C
Jaar : 2013
Journal : PLoS One
Volume : 8(8)
Pagina's : e66848

Luminal breast cancer: from biology to treatment.

Auteurs : Ignatiadis M, Sotiriou C
Jaar : 2013
Journal : Nat Rev Clin Oncol
Volume : 10(9)
Pagina's : 494-506

PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer.

Auteurs : Loi S, Michiels S, Baselga J, Bartlett JM, Singhal SK, Sabine VS, Sims AH, Sahmoud T, Dixon JM, Piccart-Gebhart M, Sotiriou C
Jaar : 2013
Journal : PLoS One
Volume : 8(1)
Pagina's : e53292

Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers.

Auteurs : Bianchini G, Pusztai L, Karn T, Iwamoto T, Rody A, Kelly CM, Müller V, Schmidt M, Qi Y, Holtrich U, Becker S, Santarpia L, Fasolo A, Del Conte G, Zambetti M, Sotiriou C, Haibe-Kains B, Symmans WF, Gianni L
Jaar : 2013
Journal : Breast Cancer Res
Volume : 15(5)
Pagina's : R86

Breast cancer and melanoma cell line identification by FTIR imaging after formalin-fixation and paraffin-embedding.

Auteurs : Verdonck M, Wald N, Janssis J, Yan P, Meyer C, Legat A, Speiser DE, Desmedt C, Larsimont D, Sotiriou C, Goormaghtigh E
Jaar : 2013
Journal : Analyst
Volume : 138(14)
Pagina's : 4083-91

Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.

Auteurs : Campone M, Bachelot T, Gnant M, Deleu I, Rugo HS, Pistilli B, Noguchi S, Shtivelband M, Pritchard KI, Provencher L, Burris HA, Hart L, Melichar B, Hortobagyi GN, Arena F, Baselga J, Panneerselvam A, Héniquez A, El-Hashimyt M, Taran T, Sahmoud T, Piccart-Gebhart M
Jaar : 2013
Journal : Eur. J. Cancer
Volume : 49(12)
Pagina's : 2621-32

Gonadotropin-Releasing Hormone Agonist for the Prevention of Chemotherapy-Induced Ovarian Failure in Patients With Lymphoma: 1-Year Follow-Up of a Prospective Randomized Trial.

Auteurs : Demeestere I, Brice P, Peccatori FA, Kentos A, Gaillard I, Zachee P, Casasnovas RO, Van Den Neste E, Dechene J, De Maertelaer V, Bron D, Englert Y
Jaar : 2013
Journal : J. Clin. Oncol.
Volume : 31(7)
Pagina's : 903-9

How Long is Enough - Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast Cancer.

Auteurs : Pinto AC, de Azambuja E, Piccart-Gebhart M
Jaar : 2013
Journal : Breast Care (Basel)
Volume : 8(4)
Pagina's : 264-269

Asthma control measurement using five different questionnaires: A prospective study.

Auteurs : Vermeulen F, de Meulder I, Paesmans M, Muylle I, Bruyneel M, Ninane V
Jaar : 2013
Journal : Respir Med
Volume : 107(9)
Pagina's : 1314-21